HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

Second clinical candidate from HUTCHMED’s next-generation ATTC platform —— Leveraging synergy through simultaneous inhibition of PAM pathway ...
Healio

Low-dose aspirin reduces colorectal cancer recurrence for patients with PI3K mutations

Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...
MedPage Today

Early Promise for PI3K Inhibitor in Brain Metastases

HOUSTON -- Two-thirds of patients with PI3K-mutant brain metastases responded to the maximum tolerated dose (MTD) of the small-molecule inhibitor paxalisib plus radiation therapy (RT), a small phase I ...
ascopubs.org

Artificial intelligence–enhanced biomarker analysis of WNT, TGF-β, and PI3K pathway alterations in FOLFOX-treated early-onset colorectal cancer in high-risk populations.

WNT pathway alterations in bevacizumab-treated early-onset colorectal cancer: An artificial intelligence–driven and disparity-aware precision oncology analysis. Longitudinal clinical validation of the ...
Pharmabiz

Hutchmed begins global clinical trial of PI3K/PIKK-EGFR ATTC candidate HMPL-A580 in patients with solid tumours

Hong Kong, Shanghai Friday, March 6, 2026, 10:00 Hrs [IST] ...